Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 18

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 18
---
: “MTSL”). From November 2015 to March 2017, Mr.Ronen Twito served as Deputy Chief Executive Officer and CFO at Cellect Biotechnology Ltd. (Nasdaq: “APOP”). From May 2014 until November 2015, he served as Vice President of Finance at BioBlast Pharma Ltd. (Nasdaq: “ORPN”) (merged in later stage with Enlivex Therapeutics, Nasdaq: “ENLV”). From June 2009 to April 2014, Mr.Twito served as Deputy Chief Executive Officer and CFO at XTL Biopharmaceuticals Ltd. (Nasdaq: “XTLB”). Mr.Twito served as the Chief Executive Officer of InterCure Ltd. (subsidiary of XTL) from 2011 to 2012 (TASE: “INCR”). From November 2004 to June 2009 he served as Corporate Finance Director at Leadcom Integrated Solutions (London, AIM: “LEAD”). From January 2000 to November 2004, he served as Audit Manager at EY. Mr.Twito is a Certified Public Accountant (CPA) in Israel and holds a bachelor’s degree in Business Administration and Accounting from the College of Management Academic Studies, Israel. He maintains active membership in the Institute of Certified Public Accountants in Israel. Prof. Michel Revel:Prof. Michel Revel, MD, PhD, has served as Kadimastem’s Chief Scientific Officer and board member since 2010, and is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. In January 1968, he was appointed as Senior Scientist of the Department of Biochemistry at the Weizmann Institute of Science in Rehovot, Israel, where he has been a full -timeProfessor since January 1973, heading for several periods the Departments of Virology and of Molecular Genetics. His research on Interferon, its mechanisms of action and the isolation of the human Interferon -betagene, has led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif ®, a Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory has focused on human embryonic stem cells (“hESC”) and has succeeded in producing nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating